New drug combo takes on advanced cancers
NCT ID NCT07665970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether two experimental drugs, SCTB41 and SCTB39G, given together every three weeks, are safe and can shrink tumors in adults with advanced solid tumors that have not responded to standard treatments. The study will enroll 112 participants across multiple centers. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SCTB41 and SCTB39G (two experimental drugs given together by IV every 3 weeks)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapy.
- What could go wrong
- This is an early phase 1/2 trial with only 112 participants, so it is too soon to know if the combination is safe or effective. Side effects are unknown and could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo targets Hard-to-Treat cancers
- Experimental injection trains immune cells inside the body to fight cancer
- New combo therapy takes on advanced cancers
- New hope for advanced cancer patients as experimental drug JSKN021 enters first human tests
- New drug CS231295 enters first human trial for tough cancers
- New hope for advanced cancer: AK150 drug trial launches